Insider · CIK 0001678152
Jason A Keyes
Files at ACTU (ACTUATE THERAPEUTICS, INC.), EQ (Equillium, Inc.), BLSM (BlossomHill Therapeutics, Inc.). First filing Nov 15, 2024, latest Aug 10, 2026.
Jason A Keyes files SEC Form 4 as CFO and director at EQ (Equillium, Inc.), and also at BLSM (BlossomHill Therapeutics, Inc.), ACTU (ACTUATE THERAPEUTICS, INC.). Since Nov 15, 2024, Jason A Keyes has reported 1 open-market buy worth $11k and 2 open-market sells worth $14k, the latest filed on Aug 10, 2026.
A track record needs three past buys with six months of prices behind them; Jason A Keyes has 0, so none is measured yet.
The newest scored trade: bought $11k of BLSM on Aug 10, 2026, filed Aug 10, 2026, scored 45 (moderate). In the last 12 months: 1 buy worth $11k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EQ: Equillium, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | BlossomHill Therapeutics, Inc. | $11k 700 shares | - | - | |
| 7Weak | Equillium, Inc. | $6,500 10,000 shares | -21% | - | |
| 7Weak | Equillium, Inc. | $7,000 10,000 shares | -17% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 8, 2025 | EQ Equillium, Inc. | 88,913 0.25% of outstanding | $28k | Jul 7, 2025 | $3,860 |
| Jun 12, 2025 | EQ EQUILLIUM, INC. | 10,000 0.03% of outstanding | $3,860 | Jun 12, 2025 | none |
| Nov 14, 2024 | EQ EQUILLIUM INC | 20,000 0.06% of outstanding | $16k | Nov 14, 2024 | $8,051 |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | POpen-market purchase Common Stock | +700 | $16.00 | $11k | 700 | Aug 10, 2026 |
| Aug 6, 2026 | BLSM BlossomHill Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +56,746 | $0.00 | $0 | 56,746 | Aug 10, 2026 |
| May 21, 2026 | ACTU ACTUATE THERAPEUTICS, INC. | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 22, 2026 |
| May 22, 2025 | ACTU ACTUATE THERAPEUTICS, INC. | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +70,000 | - | - | 70,000 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -70,000 | - | - | 0 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +90,000 | - | - | 90,000 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -90,000 | - | - | 0 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | - | - | 100,000 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -100,000 | - | - | 0 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +125,000 | - | - | 125,000 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -125,000 | - | - | 0 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +175,000 | - | - | 175,000 | Feb 19, 2025 |
| Feb 14, 2025 | EQ Equillium, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -175,000 | - | - | 0 | Feb 19, 2025 |
| Jan 23, 2025 | EQ Equillium, Inc. | SOpen-market sale Common Stockindirect: By The Keyes Trust Dated September 10, 200410b5-1 | -10,000 | $0.65 | $6,500 | 37,720 | Jan 24, 2025 |
| Dec 10, 2024 | EQ Equillium, Inc. | AGrant or award Common Stock | +15,000 | $0.54 | $8,100 | 88,913 | Jan 6, 2025 |
| Jan 2, 2025 | EQ Equillium, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jan 6, 2025 |
| Nov 14, 2024 | EQ Equillium, Inc. | SOpen-market sale Common Stockindirect: By The Keyes Trust Dated September 10, 200410b5-1 | -10,000 | $0.70 | $7,000 | 47,720 | Nov 15, 2024 |
Questions about Jason A Keyes
Answered from the filings on this page, as of the latest one.
Is Jason A Keyes buying or selling?
In the last 12 months Jason A Keyes reported 1 open-market buy worth $11k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $11k of BLSM on Aug 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Jason A Keyes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jason A Keyes has 0.
Where does Jason A Keyes file Form 4?
Jason A Keyes has filed Form 4 at EQ (Equillium, Inc.) as Chief Financial Officer; BLSM (BlossomHill Therapeutics, Inc.) as Chief Financial Officer; ACTU (ACTUATE THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.